Astrazeneca AB v Comptroller-General of Patents, Designs and Trade Marks

Core Citations

CONSIDERS

• Synthon BV v Merz Pharma GmbH & Company

REPORTED OPINION OF in

• 2013 RPC 25

APPLIED in

• Abraxis Bioscience LLC v The Comptroller-General of Patents

REFERRED in

• Glaxosmithkline Biologicals Sa v Comptroller-general of Patents, Designs and Trade Marks

This document cites

• Synthon BV v Merz Pharma GmbH & Company
• AHP Manufacturing BV v Bureau voor de Industriële Eigendom.
• Reino de España contra Consejo de la Unión Europea.
• Hässle AB v Ratiopharm GmbH.
• Pharmacia Italia SpA, formerly Pharmacia & Upjohn SpA.



See all quotations

• Yamanouchi Pharmaceutical Co. Ltd contra Comptroller-General of Patents, Designs and Trade Marks.
• Neurim Pharmaceuticals (1991) Ltd v Comptroller-General of Patents.
• Novartis AG, University College London and Institute of Microbiology and Epidemiology v Comptroller-General of Patents, Designs and Trade Marks for the United Kingdom (C-207/03) and Ministre de l'Économie v Millennium Pharmaceuticals Inc. (C-252/03).
• Farmitalia Carlo Erba Srl.
• Synthon BV v Merz Pharma GmbH & Co. KGaA.
• Massachusetts Institute of Technology.
• Generics (UK) Ltd v Synaptech Inc.
• Council Regulation (EEC) No 1768/92 of 18 June 1992 concerning the creation of a supplementary protection certificate for medicinal products
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
• Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by Law, Regulation or Administrative Action relating to proprietary medicinal products
• Council Regulation (EEC) No 2309/93 of 22 July 1993 laying down Community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Agency for the Evaluation of Medicinal Products
• Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance)Text with EEA relevance
• Commission Decision of 17 October 2001 authorising the United Kingdom to grant aid to two coal production units for 2000 and 2001 (Text with EEA relevance) (notified under document number C(2001) 3081)
• Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use (Text with EEA relevance)
• Directive 2001/82/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to veterinary medicinal products
• Council Directive 81/851/EEC of 28 September 1981 on the approximation of the laws of the Member States relating to veterinary medicinal products